Abstract
BRAF mutations have emerged as an important predictive biomarker for metastasized melanoma. Other types of cancer may also benefit from BRAF mutation-targeted therapies. In biliary tract cancer, reported BRAF mutation rates are highly controversial, ranging from 0 to 33% in adenocarcinoma of the gallbladder and 0 to 22% in cholangiocarcinoma. We here analyzed tissue microarrays of a large cohort of biliary tract cancer (n=377) including 159 intrahepatic cholangiocarcinomas, 149 extrahepatic cholangiocarcinomas, and 69 adenocarcinomas of the gallbladder for BRAF V600E mutation using a highly sensitive immunohistochemical screening approach implementing the BRAF V600E protein-specific antibody VE1. All VE1-positive cases as well as 42 VE1-negative cases were additionally analyzed by Sanger sequencing. In total, only 5 VE1-positive cases were detected (5/377; 1%). BRAF V600E mutation was confirmed by direct sequencing in all cases. All 5 mutated cases were intrahepatic cholangiocarcinomas (5/159; 3%). None of the extrahepatic cholangiocarcinomas and adenocarcinomas of the gallbladder were VE1 positive. Apart from the subtype restriction of BRAF V600E mutation to intrahepatic cholangiocarcinoma and a female predominance (4 female, 1 male), no significant correlation with clinicopathological data and patient outcome was detected. In conclusion, we demonstrate that BRAF V600E mutation is a rare event in biliary tract cancer, accounting for only 1% of all subtypes, and is restricted to intrahepatic cholangiocarcinoma. In addition, we demonstrate that VE1 immunohistochemistry is a feasible approach to routinely screen for BRAF V600E mutation in biliary tract cancer patients, thereby facilitating the detection of rare patients who may benefit from BRAF mutation-targeted therapies.
Similar content being viewed by others
Main
Biliary tract cancers are a diverse group of tumors that arise from the biliary tract epithelium. Biliary tract cancers can be divided into three major clinical phenotypes: cholangiocarcinomas of intrahepatic and extrahepatic origin and adenocarcinomas of the gallbladder. In the clinical context, biliary tract cancers are often treated as one disease, although there is evidence of genetic heterogeneity as well as differences in clinical behavior.1 Most patients with biliary tract cancer present with unresectable or metastatic disease. Despite systemic chemotherapy, prognosis remains poor and to date there are no molecular-targeted therapies tailored to biliary tract cancer.2
The RAS/RAF/MEK/ERK mitogen-activated protein (MAP) kinase pathway regulates cellular proliferation, survival, and migration, and is aberrantly activated in the majority of solid tumors. Mutation of the BRAF gene is one mechanism of constitutive activation and occurs in many human cancers including cutaneous melanoma, papillary thyroid carcinoma, borderline ovarian carcinoma, pleomorphic xanthoastrocytoma, colorectal carcinoma, non-small cell lung carcinoma, and hairy cell leukemia, among others.3, 4, 5, 6 The most common BRAF mutation results in a single amino-acid substitution of valine for glutamic acid at residue 600 (V600E). Early publications referred to codon 600 mutations as codon 599 mutations. In 2003, the BRAF sequence was updated with the insertion of 3 bp in the coding sequence, resulting in a new number of the hotspot codon (600 instead of 599). For metastatic melanoma, small-molecule inhibitors of BRAF V600E protein have demonstrated clinical activity and have rapidly changed standard treatment of BRAF-mutated melanoma patients.7, 8, 9 Similarly, these targeted therapies might also have antitumor activity in various other BRAF-mutated neoplasias.10, 11, 12, 13, 14 Accurate and rapid detection of BRAF mutations in metastatic melanoma is therefore essential for optimal patient care and may possibly be also required in other tumor entities in the near future.
An analysis of available data on BRAF V600E and non-V600E mutations revealed that BRAF mutation frequencies are highly controversial in biliary tract cancers ranging from 0 to 33% for BRAF V600E (see Table 1). As most studies with high BRAF mutation rates were performed on European cohorts, a recent review raised the question of whether these discordant results represent a regional difference in the genetics of biliary tract cancer.2
In this study, we investigated a large collection of biliary tract cancers for BRAF V600E mutations using a novel mutation-specific antibody (clone VE1) that specifically binds to BRAF V600E-mutated protein that is in general located in the cytoplasm. VE1 immunohistochemistry has proven to be highly sensitive and specific for various tumor types, including melanoma,15, 16, 17, 18, 19 thyroid carcinoma,20, 21 colorectal carcinoma,22, 23 ganglioglioma,24 and hairy cell leukemia,25 among others.
The large numbers of the cohort investigated in this study should allow (1) to gain a more solid data basis for estimating the frequency of BRAF V600E mutation in biliary tract cancer, thereby partly resolving the discrepancy of the previously reported mutation rates, and (2) detecting associations of BRAF mutation status with subtypes and possibly other clinicopathological factors. Furthermore, we present a feasible approach to screen biliary tract cancer specimen for BRAF V600E mutation.
Materials and methods
Clinicopathological Characteristics of Biliary Tract Cancer Patients
Tissue samples from 377 patients (median age 64.1 years) who underwent bile duct and/or liver surgery at the University Hospital Heidelberg between 1995 and 2010 were included in this study. Only patients with primary adenocarcinomas of the biliary tract and without other known malignancies at the time of diagnosis were included. Biliary tract cancers consisted of 159 intrahepatic cholangiocarcinomas, 149 extrahepatic cholangiocarcinomas (106 perihilar and 43 distal), and 69 adenocarcinomas of the gallbladder. None of the patients received radio- and/or chemotherapy before surgery. Tumors were restaged according to the 7th TNM Classification of Malignant Tumors and classified after the World Health Organization (WHO) tumor classification system (WHO Classification of Tumours of the Digestive System, 4th edn, 2010) by two experienced pathologists (BG and WW). A summary of clinicopathological data is given in Table 2. The use of the tissues for this study was approved by the institutional ethics committee (206/05).
Tissue Microarray Construction
From all 377 biliary tract cancers, 3 μm sections were cut and stained with H&E. Representative areas were marked by two experienced pathologists (BG and WW). For each case, tumor tissue cores (1.0 mm diameter) from the selected representative tumor areas were punched out of the sample tissue blocks and embedded into a new paraffin array block using a tissue microarrayer (Beecher Instruments, Woodland, CA, USA).
Immunohistochemistry
Tissue microarray blocks were cut to 3 μm sections. BRAF V600E protein automated immunohistochemistry (clone VE1) was performed as previously described using the Ventana UltraView chemistry.25 Scoring of immunostaining results was performed by two experienced observers (BG and DC) blinded to all clinicopathological and genetic data. Immunoreaction was scored positive, when viable tumor cells showed a nonambiguous cytoplasmic staining for VE1. A faint diffuse staining, any type of isolated nuclear staining, weak staining of single interspersed cells, or staining of monocytes/macrophages was not considered positive.
PCR Amplification and Direct Sequencing
In all selected cases (all immunopositive tumors and 42 randomly chosen immunohistochemistry-negative control intrahepatic cholangiocarcinoma cases), we performed direct sequencing of BRAF exon 15 as previously described.3 In addition, we tested BRAF V600E-mutated cases for KRAS hotspot mutations by sequencing (complete exon 1) using standard primers. Microdissection was performed if tumor content was <60%.
Statistical Analyses
Statistical analyses were performed with the statistical computing environment R version 2.15.1. Correlation analyses of BRAF V600E status with clinicopathological variables were assessed with Fisher’s exact test. Univariate survival analysis was performed for overall survival by generation of Kaplan–Meier curves. Significance of differences between the groups was assessed using the log-rank test. The P-values of <0.05 were considered significant.
Results
Frequency of BRAF V600E Mutation in Biliary Tract Cancer and Correlation with Clinicopathological Data
Our immunohistochemical screen of 377 biliary tract cancers revealed 5 VE1-positive cases (1%). Immunoreaction was cytoplasmic, moderate to strong, and homogenous, staining all observable viable tumor cells in all five cases. Analysis of biliary tract cancer subtypes demonstrated that all 5 positive cases were intrahepatic cholangiocarcinomas (5/159, 3%), whereas all extrahepatic cholangiocarcinomas (n=149) and adenocarcinomas of the gallbladder (n=69) were VE1 negative (Figure 1 and Table 2). BRAF V600E mutation was confirmed by Sanger sequencing in all five cases. In 42 randomly chosen VE1 immunonegative intrahepatic cholangiocarcinoma control cases, no BRAF V600E and no other exon 15 hotspot mutation was detected by sequencing. Among the BRAF-mutated cases, no KRAS mutations were detected (data not shown). Despite the low number of detected mutations, the subtype restriction of BRAF V600E mutation to intrahepatic cholangiocarcinoma was statistically significant (P=0.01). A statistically nonsignificant female predominance (4 female, 1 male; P=0.37), but no further correlation of cases harboring BRAF V600E mutation with clinicopathological data or specific etiology (such as primary sclerosing cholangitis, HCV infection, Caroli disease), was detected (Table 2).
Correlation of BRAF V600E Mutation Status with Survival of Intrahepatic Cholangiocarcinoma Patients
Among intrahepatic cholangiocarcinoma, patients with BRAF V600E-mutated tumors did not show an altered overall survival probability when compared with patients with BRAF wild-type tumors (Figure 2; P=0.38).
Discussion
This analysis of a comprehensive biliary tract cancer cohort demonstrates that BRAF V600E mutation is a rare event in biliary tract cancer, accounting for only 1% of all cases (n=377). Our findings are in line with recently published smaller series detecting BRAF mutations in 1% to 4% of evaluated cases.26, 27, 28 We cannot confirm the exceedingly high mutation rates detected in early BRAF studies of European cohorts,29, 30 and conclude that the previously assumed regional difference in the genetics of biliary tract cancer in Europe versus the Americas is not existent.2 Our data further demonstrate that BRAF mutations are restricted to intrahepatic cholangiocarcinomas and account for 3% in this subgroup. Comparing these results with earlier studies demonstrates that this restriction to intrahepatic cholangiocarcinoma is also evident in most preceding studies, although the case numbers were previously too low for further statistical conclusions (Table 1). A single early study reported several BRAF V600E-mutated cases among adenocarcinomas of the gallbladder.30 Our data and the data of two other groups implementing diverse methods for mutation detection weaken the generalizability of this early observation in adenocarcinomas of the gallbladder.31, 32
Most intrahepatic cholangiocarcinomas are diagnosed at an unresectable stage, for which only palliative chemotherapy remains as therapeutic option.1, 2 Thus, detection of a potentially treatable BRAF V600E mutation may represent an additional treatment option for these patients. The exclusive detection of BRAF V600E mutation in intrahepatic cholangiocarcinoma also has practical diagnostic implications, because the screening for BRAF V600E mutation in biliary tract cancer could be narrowed to this subtype, thereby substantially lowering the number of cases to be screened. Furthermore, our observation adds to the growing notion of a distinct molecular separation of intrahepatic and extrahepatic cholangiocarcinoma1, 2 as also recently observed for mutations of isocytrate dehydrogenase 1 and 2.32
Correlation of BRAF V600E mutation status with survival of intrahepatic cholangiocarcinoma patients did not show any significant difference. However, this conclusion is of limited validity because of the low number of observed mutated cases. In other types of cancer, BRAF mutations have shown varying association with patient mortality, but the effect is generally not independent of other tumor features, and thus BRAF status currently does not give definite prognostic implications for most tumor types.33, 34
Implementation of VE1 immunohistochemistry for the prediction of a BRAF V600E mutation has been investigated by various groups and for various types of cancer.15, 16, 17, 18, 19, 20, 21, 23, 24, 25 VE1 immunohistochemistry has the advantage of being rapid and relatively inexpensive, while the sensitivity and specificity are comparable to DNA-based methods. For pathologists, an additional well-appreciated advantage is the in situ mutation detection that provides information on the mutated cell population, as well as an additional visual sample verification that a faceless DNA sample does not offer. The utilization of such a technique seems particularly feasible when the expected rate of mutations is as low as in intrahepatic cholangiocarcinoma, and routine implementation of more work-intense methods such as direct sequencing is less attractive. Use of VE1 to screen for low-frequency BRAF V600E mutations has previously been demonstrated for primary lung adenocarcinoma and for unselected brain metastases of various histologies.35, 36
A clear disadvantage is that the immunohistochemical mutation analysis is limited to BRAF V600E. This is of highest relevance in melanoma, where depending on tumor genesis (especially sun exposure) up to 25% of BRAF mutations may be non-V600E.34 In biliary tract cancer, the vast majority of BRAF mutations reported to date were of the V600E type, with the limitation that several studies used DNA-based methods that are only able to detect a limited spectrum of BRAF mutations (eg, the Prism SNaPshot Multiplex system that can detect V600A, E, G, and M32). In two previously analyzed cholangiocarcinoma cohorts, tumors with BRAF mutations other than V600E have been reported that may potentially also respond to targeted therapy. For BRAF V600K (detected in one intrahepatic cholangiocarcinoma by Sia et al27) response of melanoma metastases has been observed in a phase II trial,37 and for BRAF V600D (detected in two cholangiocarcinomas not otherwise specified by Tannapfel et al29) in vitro inhibitor activity was shown in a melanoma cell line.38 In single instances, other rare BRAF mutations were detected (eg, BRAF K601E) for which data on potential clinical activity of BRAF inhibitors are not available. VE1 immunohistochemistry does not detect V600K, V600D, or other rare mutations,15, 16 and would thus fail to identify these potential candidates for targeted therapy. In our collection of 42 VE1-negative intrahepatic cholangiocarcinomas, we did not observe any non-V600E mutations, indicating that they altogether likely represent rare events in intrahepatic cholangiocarcinoma.
In conclusion, we demonstrate that VE1 immunohistochemistry is a feasible and valid approach for screening for BRAF V600E mutation in biliary tract cancer. In biliary tract cancer, BRAF V600E mutation is restricted to intrahepatic cholangiocarcinomas, and screening of extrahepatic cholangiocarcinomas and adenocarcinomas of the gallbladder could therefore likely be omitted. Considering that ∼70 000 new cases of intrahepatic cholangiocarcinoma are diagnosed globally every year, ∼2000 to 3000 patients are expected to harbor BRAF V600E-mutated tumors.27 These patients may benefit from targeted therapies, and BRAF mutation screening approaches—like the one presented in this study—should be evaluated for design of prospective trials for such low BRAF mutation frequency populations.
References
Blechacz B, Komuta M, Roskams T et al. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2011;8:512–522.
Hezel AF, Deshpande V, Zhu AX . Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2010;28:3531–3540.
Schindler G, Capper D, Meyer J et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121:397–405.
Michaloglou C, Vredeveld LC, Mooi WJ et al. BRAF(E600) in benign and malignant human tumours. Oncogene 2008;27:877–895.
Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949–954.
Arkenau HT, Kefford R, Long GV . Targeting BRAF for patients with melanoma. Br J Cancer 2011;104:392–398.
Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809–819.
Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507–2516.
Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358–365.
Rush S, Foreman N, Liu A . Brainstem ganglioglioma successfully treated with vemurafenib. J Clin Oncol 2013;31:e159–e160.
Kim K, Cabanillas M, Lazar AJ et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring V600EBRAF mutation. Thyroid 2013;23:1277–1283.
Falchook GS, Long GV, Kurzrock R et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012;379:1893–1901.
Dietrich S, Glimm H, Andrulis M et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012;366:2038–2040.
Andrulis M, Lehners N, Capper D et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov 2013;3:862–869.
Skorokhod A, Capper D, von Deimling A et al. Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. J Am Acad Dermatol 2012;67:488–491.
Long GV, Wilmott JS, Capper D et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013;37:61–65.
Colomba E, Helias-Rodzewicz Z, Von Deimling A et al. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 2013;15:94–100.
Lade-Keller J, Kristensen LS, Riber-Hansen R et al. A role for immunohistochemical detection of BRAF V600E prior to BRAF-inhibitor treatment of malignant melanoma? J Clin Pathol 2013;66:723–725.
Busam KJ, Hedvat C, Pulitzer M et al. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Am J Surg Pathol 2013;37:413–420.
Koperek O, Kornauth C, Capper D et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 2012;36:844–850.
Bullock M, O'Neill C, Chou A et al. Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Endocr Relat Cancer 2012;19:779–784.
Toon CW, Walsh MD, Chou A et al. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch Syndrome. Am J Surg Pathol 2013;37:1592–1602.
Capper D, Voigt A, Bozukova G et al. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer 2013;133:1624–1630.
Koelsche C, Wohrer A, Jeibmann A et al. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 2013;125:891–900.
Andrulis M, Penzel R, Weichert W et al. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 2012;36:1796–1800.
Voss JS, Holtegaard LM, Kerr SE et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol 2013;44:1216–1222.
Sia D, Hoshida Y, Villanueva A et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013;144:829–840.
Andersen JB, Spee B, Blechacz BR et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012;142:e15.
Tannapfel A, Sommerer F, Benicke M et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003;52:706–712.
Saetta AA, Papanastasiou P, Michalopoulos NV et al. Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. Virchows Arch 2004;445:179–182.
Goldenberg D, Rosenbaum E, Argani P et al. The V599E BRAF mutation is uncommon in biliary tract cancers. Mod Pathol 2004;17:1386–1391.
Borger DR, Tanabe KK, Fan KC et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012;17:72–79.
Xing M, Alzahrani AS, Carson KA et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013;309:1493–1501.
Long GV, Menzies AM, Nagrial AM et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29:1239–1246.
Ilie M, Long E, Hofman V et al. Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 2013;24:742–748.
Capper D, Berghoff AS, Magerle M et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012;123:223–233.
Long GV, Trefzer U, Davies MA et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:1087–1095.
Gentilcore G, Madonna G, Mozzillo N et al. Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations. BMC Cancer 2013;13:17.
Acknowledgements
We thank John Moyers (Institute of Pathology, University of Heidelberg) for excellent technical assistance. We thank the NCT tissue bank Heidelberg for its support (tissue banking, tissue microarray manufacturing, and technical assistance). This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG) to P Schirmacher (SFB/TRR77).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Under a licensing agreement between Ventana Medical Systems, Tucson, Arizona, and the German Cancer Research Center, DC and AvD are entitled to a share of royalties received by the German Cancer Research Center on the sales of VE1 antibody. The terms of this arrangement are being managed by the German Cancer Research Center in accordance with its conflict of interest policies.
Rights and permissions
About this article
Cite this article
Goeppert, B., Frauenschuh, L., Renner, M. et al. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Mod Pathol 27, 1028–1034 (2014). https://doi.org/10.1038/modpathol.2013.206
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/modpathol.2013.206
Keywords
This article is cited by
-
Innovative therapeutic concepts for biliary tumors
memo - Magazine of European Medical Oncology (2024)
-
Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective
Targeted Oncology (2023)
-
Cholangiocarcinoma
Nature Reviews Disease Primers (2021)
-
New Treatment Options for Advanced Biliary Tract Cancer
Current Treatment Options in Oncology (2020)
-
Cholangiokarzinome – Übersicht zur aktuellen anatomischen, histomorphologischen und morphomolekularen Klassifikation
Der Pathologe (2020)